{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:52:06Z","timestamp":1791564726392,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00436-026-08724-z","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:34:33Z","timestamp":1784165673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quinolones as anti-Toxoplasma agents: a comprehensive scoping review of in vitro and in vivo efficacy"],"prefix":"10.1007","volume":"125","author":[{"given":"Maryam","family":"Hataminejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Emami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moozhan","family":"Mofidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahbobeh","family":"Montazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"8724_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/DDDT.S60973","volume":"11","author":"PH Alday","year":"2017","unstructured":"Alday PH, Doggett JS (2017) Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug des Devel Ther 11:273\u2013293. https:\/\/doi.org\/10.2147\/DDDT.S60973","journal-title":"Drug des Devel Ther"},{"key":"8724_CR2","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/ofid\/ofwl72.1797","volume":"3","author":"PH Alday","year":"2016","unstructured":"Alday PH, Bruzual I, Pou S, Nilsen A, Riscoe MK, Doggett JS (2016) Mechanism of action of ELQ-316 against Toxoplasma gondii: evidence for QI site inhibition of cytochrome bc1. Open Forum Infect Dis 3:2249. https:\/\/doi.org\/10.1093\/ofid\/ofwl72.1797","journal-title":"Open Forum Infect Dis"},{"key":"8724_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01866-16","volume":"61","author":"PH Alday","year":"2017","unstructured":"Alday PH, Bruzual I, Nilsen A, Pou S, Winter R, Ben Mamoun C, Riscoe MK, Doggett JS (2017) Genetic evidence for cytochrome b Qi site inhibition by 4(1H)-quinolone-3-diarylethers and antimycin in Toxoplasma gondii. Antimicrob Agents Chemother 61:e01866-16. https:\/\/doi.org\/10.1128\/aac.01866-16","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR4","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1016\/j.bmcl.2004.03.070","volume":"14","author":"G Anquetin","year":"2004","unstructured":"Anquetin G, Rouquayrol M, Mahmoudi N, Santillana-Hayat M, Gozalbes R, Greiner J, Farhati K, Derouin F, Guedj R, Vierling P (2004) Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp. Bioorg Med Chem Lett 14:2773\u20132776. https:\/\/doi.org\/10.1016\/j.bmcl.2004.03.070","journal-title":"Bioorg Med Chem Lett"},{"key":"8724_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/1568005054880172","volume":"5","author":"G Anquetin","year":"2005","unstructured":"Anquetin G, Greiner J, Vierling P (2005) Quinolone-based drugs against Toxoplasma gondii and Plasmodium spp. Curr Drug Targets Infect Disord 5:227\u2013245. https:\/\/doi.org\/10.2174\/1568005054880172","journal-title":"Curr Drug Targets Infect Disord"},{"key":"8724_CR6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.ejmech.2006.07.003","volume":"41","author":"G Anquetin","year":"2006","unstructured":"Anquetin G, Greiner J, Mahmoudi N, Santillana-Hayat M, Gozalbes R, Farhati K, Derouin F, Aubry A, Cambau E, Vierling P (2006) Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones. Eur J Med Chem 41:1478\u20131493. https:\/\/doi.org\/10.1016\/j.ejmech.2006.07.003","journal-title":"Eur J Med Chem"},{"key":"8724_CR7","first-page":"198","volume":"25","author":"RM Awad","year":"2024","unstructured":"Awad RM, Eassa SM, Ibrahim HF, Hassan AA, Mansour B, Ali K, Taman A (2024) Insight of the novel synthetic quinoline-based compound PPQ-6 on chronic toxoplasmosis in immunocompromised mice. Int J Chem Biochem Sci 25:198\u2013206","journal-title":"Int J Chem Biochem Sci"},{"key":"8724_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1128\/AAC.01001-09","volume":"54","author":"LL Bajohr","year":"2010","unstructured":"Bajohr LL, Ma L, Platte C, Liesenfeld O, Tietze LF, Gross U, Bohne W (2010) In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii. Antimicrob Agents Chemother 54:517\u2013521. https:\/\/doi.org\/10.1128\/AAC.01001-09","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.vetpar.2011.12.039","volume":"187","author":"BF Barbosa","year":"2012","unstructured":"Barbosa BF, Gomes AO, Ferro EAV, Napolitano DR, Mineo JR, Silva NM (2012) Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models. Vet Parasitol 187:44\u201352. https:\/\/doi.org\/10.1016\/j.vetpar.2011.12.039","journal-title":"Vet Parasitol"},{"key":"8724_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.21608\/jesp.2023.312107","volume":"53","author":"EV Beshay","year":"2023","unstructured":"Beshay EV, Atia A, Dawoud MM, El-Refai S (2023) Efficacy of topoisomerase inhibitor II (levofloxacin) combined with Allium sativum on experimental cerebral toxoplasmosis infected mice. J Egypt Soc Parasitol 53:247\u2013258. https:\/\/doi.org\/10.21608\/jesp.2023.312107","journal-title":"J Egypt Soc Parasitol"},{"key":"8724_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1146\/annurev-micro-091014-104100","volume":"69","author":"IJ Blader","year":"2015","unstructured":"Blader IJ, Coleman BI, Chen CT, Gubbels MJ (2015) Lytic cycle of Toxoplasma gondii: 15 years later. Annu Rev Microbiol 69:463\u2013485. https:\/\/doi.org\/10.1146\/annurev-micro-091014-104100","journal-title":"Annu Rev Microbiol"},{"key":"8724_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fcimb.2017.00340","volume":"7","author":"RJ da Silva","year":"2017","unstructured":"da Silva RJ, Gomes AO, Franco PS, Pereira AS, Milian ICB, Ribeiro M, Fiorenzani P, dos Santos MC, Mineo JR, da Silva NM, Ferro EAV, Barbosa BF (2017) Enrofloxacin and toltrazuril are able to reduce Toxoplasma gondii growth in human BeWo trophoblastic cells and villous explants from human third trimester pregnancy. Front Cell Infect Microbiol 7:340. https:\/\/doi.org\/10.3389\/fcimb.2017.00340","journal-title":"Front Cell Infect Microbiol"},{"key":"8724_CR13","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.ijpara.2006.08.004","volume":"36","author":"E Del Cacho","year":"2006","unstructured":"Del Cacho E, Gallego M, Pages M, Monteagudo L, S\u00e1nchez-Acedo C (2006) Effect of the quinolone coccidiostat decoquinate on the rearrangement of chromosomes of Eimeria tenella. Int J Parasitol 36:1473\u20131481. https:\/\/doi.org\/10.1016\/j.ijpara.2006.08.004","journal-title":"Int J Parasitol"},{"key":"8724_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/20477724.2022.2083977","volume":"117","author":"S Dian","year":"2023","unstructured":"Dian S, Dian S, Ganiem AR, Ekawardhani S (2023) Cerebral toxoplasmosis in HIV-infected patients: a review. Pathog Glob Health 117:14\u201323. https:\/\/doi.org\/10.1080\/20477724.2022.2083977","journal-title":"Pathog Glob Health"},{"key":"8724_CR15","doi-asserted-by":"publisher","first-page":"16812","DOI":"10.1073\/pnas.1208069109","volume":"109","author":"JS Doggett","year":"2012","unstructured":"Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, Bord\u00f3n C, Charman SA, Katneni K, Schultz T, Burrows JN, Hinrichs DJ, Meunier B, Carruthers VB, Riscoe MK (2012) Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci U S A 109:16812\u201316817. https:\/\/doi.org\/10.1073\/pnas.1208069109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8724_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00535-20","volume":"64","author":"JS Doggett","year":"2020","unstructured":"Doggett JS, Schultz T, Miller AJ, Bruzual I, Pou S, Winter R, Dodean R, Zakharov LN, Nilsen A, Riscoe MK, Carruthers VB (2020) Orally bioavailable endochin-like quinolone carbonate ester prodrug reduces Toxoplasma gondii brain cysts. Antimicrob Agents Chemother 64:e00535-20. https:\/\/doi.org\/10.1128\/AAC.00535-20","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13071-021-04769-4","volume":"14","author":"JP Dubey","year":"2021","unstructured":"Dubey JP (2021) Outbreaks of clinical toxoplasmosis in humans: five decades of personal experience, perspectives and lessons learned. Parasit Vectors 14:263. https:\/\/doi.org\/10.1186\/s13071-021-04769-4","journal-title":"Parasit Vectors"},{"key":"8724_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00057-17","volume":"31","author":"IR Dunay","year":"2018","unstructured":"Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG (2018) Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev 31:e00057-17. https:\/\/doi.org\/10.1128\/CMR.00057-17","journal-title":"Clin Microbiol Rev"},{"key":"8724_CR19","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(98)08220-8","volume":"353","author":"D Dunn","year":"1999","unstructured":"Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R (1999) Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 353:1829\u20131833. https:\/\/doi.org\/10.1016\/S0140-6736(98)08220-8","journal-title":"Lancet"},{"key":"8724_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122912","volume":"638","author":"RK Eid","year":"2023","unstructured":"Eid RK, Arafa MF, Ashour DS, Essa EA, El-Wakil ES, Younis SS, El Maghraby GM (2023) Surfactant vesicles for enhanced antitoxoplasmic effect of norfloxacin: in vitro and in vivo evaluations. Int J Pharm 638:122912. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122912","journal-title":"Int J Pharm"},{"key":"8724_CR21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s11686-024-00852-9","volume":"69","author":"S Emami","year":"2024","unstructured":"Emami S, Sadeghi M, Shahdin S, Daryani A, Khalilian A, Pirestani M, Hosseini SA, Montazeri M, Hosseini Nejad Z, Sarvi S (2024) In vitro evaluation of anti-parasitic activities of quinolone-coumarin hybrids derived from fluoroquinolones and novobiocin against Toxoplasma gondii. Acta Parasitol 69:1275\u20131283. https:\/\/doi.org\/10.1007\/s11686-024-00852-9","journal-title":"Acta Parasitol"},{"key":"8724_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090203","volume":"9","author":"J Flegr","year":"2014","unstructured":"Flegr J, Prandota J, Sovi\u010dkov\u00e1 M, Israili ZH (2014) Toxoplasmosis a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE 9:e90203. https:\/\/doi.org\/10.1371\/journal.pone.0090203","journal-title":"PLoS ONE"},{"key":"8724_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jclinepi.2022.07.002","volume":"150","author":"AD Frost","year":"2022","unstructured":"Frost AD, Hr\u00f3bjartsson A, Nejstgaard CH (2022) Adherence to the PRISMA-P 2015 reporting guideline was inadequate in systematic review protocols. J Clin Epidemiol 150:179\u2013187. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.07.002","journal-title":"J Clin Epidemiol"},{"key":"8724_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10534-013-9661-z","volume":"26","author":"LR Gouvea","year":"2013","unstructured":"Gouvea LR, Martins DA, Batista DdGJ, Soeiro MdNC, Louro SRW, Barbeira PJS, Teixeira LR (2013) Norfloxacin Zn(II)-based complexes: acid base ionization constant determination, DNA and albumin binding properties and the biological effect against Trypanosoma cruzi. Biometals 26:813\u2013825. https:\/\/doi.org\/10.1007\/s10534-013-9661-z","journal-title":"Biometals"},{"key":"8724_CR25","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1128\/AAC.44.10.2771-2776.2000","volume":"44","author":"R Gozalbes","year":"2000","unstructured":"Gozalbes R, Brun-Pascaud M, Garcia-Domenech R, Galvez J, Girard PM, Doucet JP, Derouin F (2000) Anti-Toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques. Antimicrob Agents Chemother 44:2771\u20132776. https:\/\/doi.org\/10.1128\/AAC.44.10.2771-2776.2000","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.molbiopara.2013.05.008","volume":"190","author":"J Hegewald","year":"2013","unstructured":"Hegewald J, Gross U, Bohne W (2013) Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondii. Mol Biochem Parasitol 190:6\u201315. https:\/\/doi.org\/10.1016\/j.molbiopara.2013.05.008","journal-title":"Mol Biochem Parasitol"},{"key":"8724_CR27","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1086\/319370","volume":"32","author":"DC Hooper","year":"2001","unstructured":"Hooper DC (2001) Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32:S9\u2013S15. https:\/\/doi.org\/10.1086\/319370","journal-title":"Clin Infect Dis"},{"key":"8724_CR28","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1128\/aac.40.8.1855","volume":"40","author":"AA Khan","year":"1996","unstructured":"Khan AA, Slifer T, Araujo FG, Remington JS (1996) Trovafloxacin is active against Toxoplasma gondii. Antimicrob Agents Chemother 40:1855\u20131859. https:\/\/doi.org\/10.1128\/aac.40.8.1855","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1128\/aac.41.5.893","volume":"41","author":"AA Khan","year":"1997","unstructured":"Khan AA, Slifer T, Araujo FG, Polzer RJ, Remington JS (1997) Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. Antimicrob Agents Chemother 41:893\u2013896. https:\/\/doi.org\/10.1128\/aac.41.5.893","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1128\/aac.43.7.1783","volume":"43","author":"AA Khan","year":"1999","unstructured":"Khan AA, Araujo FG, Brighty KE, Gootz TD, Remington JS (1999) Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin. Antimicrob Agents Chemother 43:1783\u20131787. https:\/\/doi.org\/10.1128\/aac.43.7.1783","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1128\/aac.45.1.48-51.2001","volume":"45","author":"AA Khan","year":"2001","unstructured":"Khan AA, Slifer TR, Araujo FG, Remington JS (2001) Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii. Antimicrob Agents Chemother 45:48\u201351. https:\/\/doi.org\/10.1128\/aac.45.1.48-51.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR32","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.bbabio.2008.08.006","volume":"1777","author":"SS Lin","year":"2008","unstructured":"Lin SS, Kerscher S, Saleh A, Brandt U, Gross U, Bohne W (2008) The Toxoplasma gondii type-II NADH dehydrogenase TgNDH2-I is inhibited by 1-hydroxy-2-alkyl-4(1H)quinolones. Biochim Biophys Acta 1777:1455\u20131462. https:\/\/doi.org\/10.1016\/j.bbabio.2008.08.006","journal-title":"Biochim Biophys Acta"},{"key":"8724_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1128\/EC.00381-08","volume":"8","author":"SS Lin","year":"2009","unstructured":"Lin SS, Gross U, Bohne W (2009) Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii. Eukaryot Cell 8:877\u2013887. https:\/\/doi.org\/10.1128\/EC.00381-08","journal-title":"Eukaryot Cell"},{"key":"8724_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125705","volume":"10","author":"ES Martins-Duarte","year":"2015","unstructured":"Martins-Duarte ES, Dubar F, Lawton P, da Silva CF, Soeiro MdNC, de Souza W, Biot C, Vommaro RC (2015) Ciprofloxacin derivatives affect parasite cell division and increase the survival of mice infected with Toxoplasma gondii. PLoS ONE 10:e0125705. https:\/\/doi.org\/10.1371\/journal.pone.0125705","journal-title":"PLoS ONE"},{"key":"8724_CR35","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1021\/acsinfecdis.8b00133","volume":"4","author":"EV McConnell","year":"2018","unstructured":"McConnell EV, Bruzual I, Pou S, Winter R, Dodean RA, Smilkstein MJ, Krollenbrock A, Nilsen A, Zakharov LN, Riscoe MK, Doggett JS (2018) Targeted structure-activity analysis of endochin-like quinolones reveals potent Qi and Qo site inhibitors of Toxoplasma gondii and Plasmodium falciparum cytochrome bc1 and identifies ELQ-400 as a remarkably effective compound against acute experimental toxoplasmosis. ACS Infect Dis 4:1574\u20131584. https:\/\/doi.org\/10.1021\/acsinfecdis.8b00133","journal-title":"ACS Infect Dis"},{"key":"8724_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijpddr.2023.02.001","volume":"21","author":"J Mo","year":"2023","unstructured":"Mo J, Si H, Liu S, Zeng Q, Cai M, Liu Z, Zhang J, Fang J, Zhang J (2023) Effect of the Pseudomonas metabolites HQNO on the Toxoplasma gondii RH strain in vitro and in vivo. Int J Parasitol Drugs Drug Resist 21:74\u201380. https:\/\/doi.org\/10.1016\/j.ijpddr.2023.02.001","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"8724_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fmicb.2017.00025","volume":"8","author":"M Montazeri","year":"2017","unstructured":"Montazeri M, Sharif M, Sarvi S, Mehrzadi S, Ahmadpour E, Daryani A (2017) A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006\u20132016). Front Microbiol 8:25. https:\/\/doi.org\/10.3389\/fmicb.2017.00025","journal-title":"Front Microbiol"},{"key":"8724_CR38","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1007\/s00436-018-6027-z","volume":"117","author":"M Montazeri","year":"2018","unstructured":"Montazeri M, Mehrzadi S, Sharif M, Sarvi S, Shahdin S, Daryani A (2018) Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review. Parasitol Res 117:3045\u20133057. https:\/\/doi.org\/10.1007\/s00436-018-6027-z","journal-title":"Parasitol Res"},{"key":"8724_CR39","doi-asserted-by":"publisher","unstructured":"Platte C (2023) Inhibitorische Effekte von 1-Hydroxychinolonen auf Toxoplasma gondii [Doctoral thesis]. University of G\u00f6ttingen, G\u00f6ttingen. https:\/\/doi.org\/10.53846\/goediss-10155","DOI":"10.53846\/goediss-10155"},{"key":"8724_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26216393","volume":"26","author":"J Ramseier","year":"2021","unstructured":"Ramseier J, Imhof D, Anghel N, H\u00e4nggeli K, Beteck RM, Balmer V, Ortega-Mora LM, Sanchez-Sanchez R, Ferre I, Haynes RK, Hemphill A (2021) Assessment of the activity of decoquinate and its quinoline-O-carbamate derivatives against Toxoplasma gondii in vitro and in pregnant mice infected with T. gondii oocysts. Molecules 26:6393. https:\/\/doi.org\/10.3390\/molecules26216393","journal-title":"Molecules"},{"issue":"3","key":"8724_CR41","first-page":"941","volume":"39","author":"SMM Rashed","year":"2022","unstructured":"Rashed SMM, Abououf EA, Eraky MA, Barakat AM, Sadek SA, Mohammed HS (2022) Effects of Ciprofloxacin Loaded on Silver Nanoparticles on Murine Acute Toxoplasmosis Benha Medical Journal 39(3):941\u2013953","journal-title":"Effects of Ciprofloxacin Loaded on Silver Nanoparticles on Murine Acute Toxoplasmosis Benha Medical Journal"},{"key":"8724_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00454","author":"E Rocha-Valderrama","year":"2025","unstructured":"Rocha-Valderrama E, Rost\u00e1n S, Fern\u00e1ndez M, Liempi A, Castillo C, Mahler G, Galarza-Jarrin A, Costales JA, Pozo-Mart\u00ednez J, Olea-Azar C, Otero L, Moncada-Basualto M (2025) New derivatives of 6-nitrocoumarin-3-thiosemicarbazone exhibit improved antiparasitic activity in the placenta against Trypanosoma cruzi and Toxoplasma gondii. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00454","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2022.108344","volume":"240","author":"M Sadeghi","year":"2022","unstructured":"Sadeghi M, Sarvi S, Emami S, Khalilian A, Hosseini SA, Montazeri M, Shahdin S, Nayeri T, Daryani A (2022) Evaluation of anti-parasitic activities of new quinolones containing nitrofuran moiety against Toxoplasma gondii. Exp Parasitol 240:108344. https:\/\/doi.org\/10.1016\/j.exppara.2022.108344","journal-title":"Exp Parasitol"},{"key":"8724_CR44","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1128\/AAC.00895-06","volume":"51","author":"A Saleh","year":"2007","unstructured":"Saleh A, Friesen J, Baumeister S, Gross U, Bohne W (2007) Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases. Antimicrob Agents Chemother 51:1217\u20131222. https:\/\/doi.org\/10.1128\/AAC.00895-06","journal-title":"Antimicrob Agents Chemother"},{"key":"8724_CR45","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.1016\/j.fawpar.2019.e00049","volume":"15","author":"K Shapiro","year":"2019","unstructured":"Shapiro K, Bahia-Oliveira L, Dixon B, Dum\u00e8tre A, de Wit LA, VanWormer E, Villena I (2019) Environmental transmission of Toxoplasma gondii: oocysts in water, soil and food. Food Waterborne Parasitol 15:e00049. https:\/\/doi.org\/10.1016\/j.fawpar.2019.e00049","journal-title":"Food Waterborne Parasitol"},{"issue":"1","key":"8724_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3987\/COM-10-S(E)9","volume":"82","author":"LF Tietze","year":"2011","unstructured":"Tietze LF, Ma L (2011) Synthesis of novel 1-hydroxyquinolones with high anti-Toxoplasma activity. Heterocycles 82(1):377","journal-title":"Heterocycles"},{"issue":"2","key":"8724_CR47","first-page":"479","volume":"47","author":"E Yarsan","year":"2003","unstructured":"Yarsan E, Tanyuksel M, Koc F, Essiz D, Babur C (2003) Influence of experimentally induced toxoplasmosis (Toxoplasma gondii) on the pharmacokinetics of levofloxacin. Bullet Vet Ins Pulawy 47(2):479\u2013486","journal-title":"Bullet Vet Ins Pulawy"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00436-026-08724-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-026-08724-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-026-08724-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:02:14Z","timestamp":1791561734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00436-026-08724-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["8724"],"URL":"https:\/\/doi.org\/10.1007\/s00436-026-08724-z","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"value":"0932-0113","type":"print"},{"value":"1432-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that no Generative AI was used in the creation of this manuscript.","order":5,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}